Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study

28 Jul 2022

Abstract excerpt

Abstract Aims/hypothesis Metformin use has been associated with reduced incidence of dementia in diabetic individuals in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomisation (MR) to investigate the causal effect of metformin targets on Alzheimer’s disease and potential causal mechanisms in the brain linking the two. Methods...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Genetic Associations and Epidemiology
Share to Metabolism, Diabetes, and Cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35902387
DOI: 10.1007/s00125-022-05743-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation studyPMID 35902387Read ↗

Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomization studySemantic proximity Read ↗

Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study.Semantic proximity Read ↗

Randomized metformin and cognitive outcomes in the Diabetes Prevention Program Outcomes StudySemantic proximity Read ↗

Effects of putative metformin targets on phenotypic age and leukocyte telomere length: a mendelian randomisation study using data from the UK BiobankSemantic proximity Read ↗

Drug repurposing of metformin for Alzheimer’s disease: Combining causal inference in medical records data and systems pharmacology for biomarker identificationSemantic proximity Read ↗

Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals.Semantic proximity Read ↗

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.Semantic proximity Read ↗

Investigating Causal Relations Between Circulating Metabolites and Alzheimer’s Diseases: A Mendelian Randomization StudySemantic proximity Read ↗

Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer’s Risk in Diabetes Type II via Dual Actions: Tackling Disease Pathways and Environmental Herpesvirus TriggersSemantic proximity Read ↗

Causal association evaluation of diabetes with Alzheimer's disease and genetic analysis of antidiabetic drugs against Alzheimer's diseaseSemantic proximity Read ↗

Age at type 2 diabetes onset and risk of dementia: The modifying role of genetic susceptibility and mitochondrial function.Semantic proximity Read ↗

Causal relationship between cholesterol-lowering therapy and Alzheimer Disease: evidence from genetic correlation and Mendelian randomization studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.